HC Wainwright reiterates Buy rating on Enanta Pharma

0 min read Updated on 23 Jun 2026, 06:10 PM

Reviewed by

Radhika SScanX News Team

AI Summary

HC Wainwright & Co. analyst Brandon Folkes has reiterated a Buy rating on Enanta Pharma (NASDAQ: ENTA) with a maintained price target of $20.

*this image is generated using AI for illustrative purposes only.

HC Wainwright & Co. analyst Brandon Folkes has reiterated a Buy rating for Enanta Pharma (NASDAQ: ENTA). The firm has maintained its price target of $20 for the stock.

The rating affirmation underscores the analyst's continued confidence in the company's performance and valuation prospects. Enanta Pharma operates in the biotechnology sector, focusing on the discovery and development of small molecule drugs.

Analyst	Firm	Rating	Price Target
Brandon Folkes	HC Wainwright & Co.	Buy	$20

What upcoming clinical data readouts could serve as the primary catalysts for Enanta Pharma to reach the $20 price target?

How might the current biotech market environment impact investor sentiment towards small-cap drug developers like Enanta?

What specific pipeline advancements or partnerships is the market expecting from Enanta in the next fiscal year?

Read Next Article

Enanta advances zelicapavir into registrational Phase 2b/3 trial

0 min read Updated on 18 Jun 2026, 05:46 PM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

AI Summary

Enanta Pharmaceuticals is advancing zelicapavir into a registrational Phase 2b/3 clinical trial for high-risk adults with RSV in 4Q 2026, following a successful FDA meeting, with topline data expected in 2027.

*this image is generated using AI for illustrative purposes only.

Enanta Pharmaceuticals, Inc. is advancing zelicapavir into a registrational Phase 2b/3 clinical trial for adults at high risk of severe outcomes from respiratory syncytial virus (RSV) infection in 4Q 2026. The decision follows a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). The company also announced plans to initiate a Phase 2b clinical trial of zelicapavir in pediatric patients with RSV in 3Q 2026. Topline data for both the adult and pediatric trials are expected in 2027.

Clinical Trial Timeline

The Phase 2b portion of the registrational trial in adults will confirm the treatment effect. Enanta outlined the schedule for its upcoming clinical studies involving zelicapavir.

Trial Phase	Patient Population	Initiation Date	Topline Data Expected
Phase 2b/3	High-risk adults	4Q 2026	2027
Phase 2b	Pediatric patients	3Q 2026	2027

Regulatory Progression

The advancement to the registrational stage comes after the End-of-Phase 2 meeting with the FDA. Enanta Pharmaceuticals focuses on developing small molecule drugs for viral infections and immunological diseases.

How will the competitive landscape for RSV treatments evolve by the time zelicapavir reaches the market in 2027?

What are the potential market size and commercial opportunities for zelicapavir in high-risk adult and pediatric populations?

What regulatory challenges could arise during the Phase 2b/3 trial, and how might they impact the approval timeline?